Crossmark

Letter to the Editor Regarding: “Cost-Effectiveness of Elranatamab Versus Current Therapies for the Management of Patients with Triple-Class Exposed, Relapsed and Refractory Multiple Myeloma, Including Other Bispecific and Physician’s Choice of Treatment in Spain”

Crossref DOI link: https://doi.org/10.1007/s40487-026-00420-3

Published Online: 2026-02-27

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

van Nimwegen, Kirsten J. M.

Oguz, Mustafa

Morano, Raúl

Diels, Joris
License Information

Text and Data Mining valid from 2026-02-27

Version of Record valid from 2026-02-27
More Information

Article History

Received: 2 September 2025

Accepted: 4 February 2026

First Online: 27 February 2026

Declarations

:

: Kirsten J.M. van Nimwegen, Mustafa Oguz, Raúl Morana, and Joris Diels work for Johnson & Johnson. The authors report no other conflicts of interest in this communication.

: This letter is a response to a previously conducted cost-effectiveness analysis and does not contain any new studies within human participants or animals performed by any of the authors.

Document is current

Any future updates will be listed below